PKC412 small-molecule tyrosine kinase inhibitor: Single-compound therapy for pancreatic cancer

Cancer

Volumn 110, Issue 7, 2007, Pages 1457-1468

  El Fitori, Jamael ^a   Su, Yun ^a,b   Büchler, Peter ^a,c   Ludwig, Roman ^a   Giese, Nathalia A ^a   Büchler, Markus W ^a,c   Quentmeier, Hilmar ^d   Hines, Oscar J ^e   Herr, Ingrid ^a   Friess, Helmut ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SOUTHEAST UNIVERSITY   (China)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; FLT3; Pancreatic cancer; PKC412

Indexed keywords

CD135 ANTIGEN; MIDOSTAURIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FLT3 PROTEIN, HUMAN; STAUROSPORINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLT3 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR VASCULARIZATION; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL PROLIFERATION; CLINICAL TRIAL; DNA SEQUENCE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROCIRCULATION; MULTICENTER STUDY; PANCREAS TUMOR; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TANDEM REPEAT; TUMOR CELL LINE; VASCULARIZATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICROCIRCULATION; PANCREATIC NEOPLASMS; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTEIN KINASE C; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; STAUROSPORINE; TANDEM REPEAT SEQUENCES; TUMOR CELLS, CULTURED;

EID: 34648819666     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22931     Document Type: Article

References (35)

1. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
2. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
3. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-3516.
4. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
5. Buchler P, Reber HA, Lavey RS, et al. Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res. 2004;120:295-303.
6. Buchler P, Reber HA, Buchler MW, Friess H, Hines OJ. VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg. 2002;236:738-749.
7. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493-502.
8. Drexler HG, Meyer C, Quentmeier H. Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells. Leuk Lymphoma. 1999;33:83-91.
9. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 2003;17:120-124.
10. Drexler HG, Quentmeier H. FLT3: receptor and ligand. Growth Factors. 2004;22:71-73.
11. Rosnet O, Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog. 1993; 4:595-613.
12. Bao L, Wang X, Ryder J, et al. Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations. Eur J Haematol. 2006;77:35-45.
13. Kiyoi H, Naoe T. FLT3 mutations in acute myeloid leukemia. Methods Mol Med. 2006;125:189-197.
14. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.
15. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
16. Ryschich E, Huszty G, Wentzensen N, et al. Effect of Flt3 ligand gene transfer in experimental pancreatic cancer. Int J Colorectal Dis. 2007;22:215-223.
17. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1:433-443.
18. Fabbro D, Ruetz S, Bodis S, et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000;15:17-28.
19. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54-60.
20. Buchler P, Gazdhar A, Schubert M, et al. The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg. 2005;242:791-800, discussion 800-801.
21. Kleeff J, Friess H, Berberat PO, Martignoni ME, Z'graggen K, Buchler MW. Pancreatic cancer-new aspects of molecular biology research. Swiss Surg. 2000;6:231-234.
22. Timeus F, Ricotti E, Crescenzio N, et al. Flt-3 and its ligand are expressed in neural crest-derived tumors and promote survival and proliferation of their cell lines. Lab Invest. 2001;81:1025-1037.
23. Buchler P, Reber HA, Eibl G, et al. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int J Oncol. 2005;27:1125-1130.
24. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Genomic structure of human FLT3: implications for mutational analysis. Br J Haematol. 2001;113:1076-1077.
25. Buchler P, Reber HA, Buchler MW, Friess H, Lavey RS, Hines OJ. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer. 2004;100:201-210.
26. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271-279.
27. Buchler P, Gukovskaya AS, Mouria M, et al. Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid. Pancreas. 2003;26:264-273.
28. Buchler P, Reber HA, Roth MM, Shiroishi M, Friess H, Hines OJ. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia. 2007;9:119-127.
29. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;94:883-893.
30. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002;38:1564-1579.
31. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer. 1996;32A:2474-2484.
32. von Marschall Z, Cramer T, Hocker M, et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology. 2000;119:1358-1372.
33. Buchler P, Reber HA, Ullrich A, et al. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery. 2003;134:772-782.
34. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest FIk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72:835-846.
35. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 2003;3:459-469.